Potential effect of Zika virus infection on human male fertility?

Carregando...
Imagem de Miniatura
Citações na Scopus
21
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
INST MEDICINA TROPICAL SAO PAULO
Citação
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.60, article ID UNSP e64, 4p, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Zika virus (ZIKV) sexual transmission and prolonged viral shedding in semen have been previously reported, suggesting a strong viral affinity for genital tissues. A transient impact of ZIKV on male fertility was shown in animal and human studies. Methods: Adult male patients with confirmed ZIKV infection diagnosed in the city of Araraquara, Brazil during the epidemic season of 2016 were invited one year after the acute infection to respond to a questionnaire of genital symptoms and to provide a semen sample for molecular ZIKV testing and spermogram analysis, as well as a serum sample for hormonal testing. Results: 101 of 187 tested patients had positive ZIKV RT-PCR in plasma and/or urine samples (54%. 72 women and 29 men). Of 15 adult male participants for whom telephone contact was successful, 14 responded to the questionnaire of genital symptoms and six consented to provide a semen sample at a median of 12 months after the acute infection. We report abnormal spermogram results from patients one year after confirmed ZIKV infection. Conclusions: Our findings suggest a possible long-term detrimental effect of ZIKV infection on human male fertility that has to be further explored in well-characterized samples from cohort studies conducted in ZIKV-endemic areas.
Palavras-chave
Zika virus, exual transmission, Shedding, Semen, Spermogram, Fertility, Brazil
Referências
  1. Arsuaga M, 2016, LANCET INFECT DIS, V16, P1107, DOI 10.1016/S1473-3099(16)30320-6
  2. Brasil. Ministerio da Saude, 2015, PROT VIG RESP OC MIC
  3. Brasil P, 2016, NEW ENGL J MED, V375, P2321, DOI 10.1056/NEJMoa1602412
  4. Duffy MR, 2009, NEW ENGL J MED, V360, P2536, DOI 10.1056/NEJMoa0805715
  5. Govero J, 2016, NATURE, V540, P438, DOI 10.1038/nature20556
  6. Joguet G, 2017, LANCET INFECT DIS, V17, P1200, DOI 10.1016/S1473-3099(17)30444-9
  7. Lanciotti RS, 2008, EMERG INFECT DIS, V14, P1232, DOI 10.3201/eid1408.080287
  8. Mansuy JM, 2016, LANCET INFECT DIS, V16, P1106, DOI 10.1016/S1473-3099(16)30336-X
  9. Matheron S, 2016, CLIN INFECT DIS, V63, DOI 10.1093/cid/ciw509
  10. Musso D, 2014, EUROSURVEILLANCE, V19, P6, DOI 10.2807/1560-7917.ES2014.19.14.20761
  11. Nicastri E, 2016, EUROSURVEILLANCE, V21, P6, DOI 10.2807/1560-7917.ES.2016.21.32.30314
  12. Sherley M, 2018, SEX HEALTH, V15, P183, DOI 10.1071/SH17046
  13. SVS/MS-Secretaria de Vigilancia em Saude/Ministerio da Saude, 2018, B EPIDEMIOL, V49, P1
  14. Turmel JM, 2016, LANCET, V387, P2501, DOI 10.1016/S0140-6736(16)30775-9
  15. Uraki R, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1602899
  16. World Health Organization, 2010, WHO LAB MAN EX PROC